Kalaris Therapeutics Stock Price, News & Analysis
KLRS
NASDAQ
Company Description
Welcome to the overview page for Kalaris Therapeutics (KLRS), where you can find comprehensive stock information and company updates.
Explore the latest news on strategic partnerships, quarterly and annual financial results, and regulatory filings including SEC reports and insider transactions.
Visualize performance trends using the interactive price chart, and keep track of upcoming events such as earnings calls, dividend dates, and investor conferences.
Stock Performance
$6.24
0.00%
0.00
Last updated: November 29, 2025 at 12:59
-45.6 %
Performance 1 year
$120.4M
18.7M
Latest News
SEC Filings
Financial Highlights
$0
Revenue (TTM)
-$10,196,000
Net Income (TTM)
-$2.52
-$7,441,000
Operating Cash Flow
14.31
-$10,354,000
Upcoming Events
DEC
31
December 31, 2025
Clinical
Phase 1a data release
Initial data for Phase 1a single ascending dose trial
JUL
01
July 1, 2026 - December 31, 2026
Clinical
Phase 1b/2 data readout
Initial Phase 1b/2 MAD study data release for TH103
JUL
01
July 1, 2026 - December 31, 2026
Clinical
Phase 1b/2 data release
Initial data for Phase 1b/2 multiple ascending dose nAMD trial
JUL
01
July 1, 2026 - December 31, 2026
Clinical
Phase1b/2 data readout
Expected clinical readout from Phase 1b/2 MAD study of TH103
Short Interest History
Last 12 Months
Loading short interest data...
Days to Cover History
Last 12 Months
Loading days to cover data...
Frequently Asked Questions
What is the current stock price of Kalaris Therapeutics (KLRS)?
The current stock price of Kalaris Therapeutics (KLRS) is $6.24 as of November 28, 2025.
What is the market cap of Kalaris Therapeutics (KLRS)?
The market cap of Kalaris Therapeutics (KLRS) is approximately 120.4M. Learn more about what market capitalization means .
What is the revenue (TTM) of Kalaris Therapeutics (KLRS) stock?
The trailing twelve months (TTM) revenue of Kalaris Therapeutics (KLRS) is $0.
What is the net income of Kalaris Therapeutics (KLRS)?
The trailing twelve months (TTM) net income of Kalaris Therapeutics (KLRS) is -$10,196,000.
What is the earnings per share (EPS) of Kalaris Therapeutics (KLRS)?
The diluted earnings per share (EPS) of Kalaris Therapeutics (KLRS) is -$2.52 on a trailing twelve months (TTM) basis. Learn more about EPS .
What is the operating cash flow of Kalaris Therapeutics (KLRS)?
The operating cash flow of Kalaris Therapeutics (KLRS) is -$7,441,000. Learn about cash flow.
What is the current ratio of Kalaris Therapeutics (KLRS)?
The current ratio of Kalaris Therapeutics (KLRS) is 14.31, indicating the company's ability to pay short-term obligations. Learn about liquidity ratios.
What is the operating income of Kalaris Therapeutics (KLRS)?
The operating income of Kalaris Therapeutics (KLRS) is -$10,354,000. Learn about operating income.